Global Anticoagulation Therapy Market Growth (Status and Outlook) 2023-2029

Global Anticoagulation Therapy Market Growth (Status and Outlook) 2023-2029

Anticoagulants, commonly referred to as blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and dialysis equipment.

LPI (LP Information)' newest research report, the “Anticoagulation Therapy Industry Forecast” looks at past sales and reviews total world Anticoagulation Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Anticoagulation Therapy sales for 2023 through 2029. With Anticoagulation Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anticoagulation Therapy industry.

This Insight Report provides a comprehensive analysis of the global Anticoagulation Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anticoagulation Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anticoagulation Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anticoagulation Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anticoagulation Therapy.

The global Anticoagulation Therapy market size is projected to grow from US$ 25320 million in 2022 to US$ 42600 million in 2029; it is expected to grow at a CAGR of 7.7% from 2023 to 2029.

Novel Oral Anticoagulants (NOACs) have major pharmacologic benefits over warfarin, which is a vitamin K antagonist, together with the rapid onset/offset of action, few drug interactions and predictable pharmacokinetics. Warfarin has a limited therapeutic window that can be strike by factors such as diet and enabling patients on warfarin to monitor their INR regularly. Novel oral anticoagulant (NOACs) is the top performing segment as an alternative to anticoagulant. Increasing number of patients with lifelong medical aid therapy, growing prevalence of blood vessel thromboembolism, arrhythmia, and stroke, acceptance of NOAC’s is raising revenue in the market, rising outpatient anticoagulation therapy, increasing number of pipeline products under clinical trials and rising heparin trade spurring the growth of anticoagulation therapy market. However, high cost of developing drugs and risk of malfunctions like increased bleeding is main issue with newer agents are expected to impact the target market negatively.

This report presents a comprehensive overview, market shares, and growth opportunities of Anticoagulation Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
NOACs
Warfarin

Segmentation by application
Hospital Associated Clinics
Independent Clinics
Pharmacy-Based Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CH Boehringer Sohn
Bristol-Myers Squibb
Johnson＆Johnson
Pfizer
Daiichi Sankyo
Portola Pharmaceuticals
Roche
Abbott

Please note: The report will take approximately 2 business days to prepare and deliver.